Published on 29/11/2025

PPQ Strategy for ATMP: Lots, Patients, and Equivalence

In the pharmaceutical industry, particularly within the realm of Advanced Therapy Medicinal Products (ATMP), the Performance Qualification (PPQ) process is critical for ensuring robustness and compliance. This comprehensive tutorial aims to provide pharmaceutical professionals with a step-by-step guide to establishing an effective PPQ for ATMPs, focusing on important facets such as viral clearance validation, closed and single-use systems, and meticulous tailoring of PPQ and Continuous Process Verification (CPV) for specific patient populations and lot equivalency.

Understanding the Fundamentals of PPQ for ATMP

Performance Qualification (PPQ) represents a vital component of process validation, allowing for the demonstration that the manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. Hence, the development of a well-structured PPQ strategy with a focused approach to lot equivalence and patient demographics is essential within the scope of cGMP compliance.

ATMPs comprise a range of products including gene therapies, somatic cell therapies, and tissue-engineered products. Their unique complexity necessitates specific regulatory considerations, prominently exemplified in governing documents such as ICH Q5A(R2). Understanding these guidelines is crucial when designing a PPQ tailored to ATMP attributes and regulatory requirements.

Central to the ATMP PPQ strategy is the identification and management of Critical Quality Attributes (CQAs), which include potency and identity parameters. These attributes can have profound implications on patient safety and effectiveness. Defining the Critical Process Parameters (CPPs) that influence CQAs is a foundational step in establishing a robust PPQ framework.

Key Components of a Successful PPQ Strategy

• Identification of CQAs: This involves defining potency, identity, and other essential attributes that the product must meet.
• Establishment of CPPs: Determines which parameters during manufacturing affect CQAs.
• Packaging of Spiking Studies: Validation of spiking studies to quantify viral clearance can aid in understanding the robustness of the process.
• Use of Closed and Single-Use Systems: Implementation of these systems is vital for maintaining sterility and minimizing contamination risks.

Framework for Developing a Tailored PPQ Strategy

Establishing a tailored PPQ strategy requires a multi-faceted approach that emphasizes collaboration among stakeholders, including Quality Assurance (QA), Quality Control (QC), Regulatory Affairs, and Clinical Operations. The following framework outlines necessary steps for the development of an effective strategy.

1. Initial Assessment and Strategy Development

The initial phase focuses on gathering detailed information about the specific ATMP product, which aids in identifying risk factors and regulatory requirements. Key activities include:

• Risk Assessment: Analyze potential risks from raw materials, manufacturing processes, and environmental factors.
• Regulatory Considerations: Understand applicable guidelines, especially those from the FDA regarding process validation.
• Stakeholder Engagement: Involve relevant departments to create shared objectives for the PPQ strategy.

2. Defining Viral Clearance Requirements

Viral clearance is critical in ensuring patient safety, particularly in ATMPs that are derived from living cells. Establishing a robust viral clearance validation strategy involves:

• Evaluation of Baseline Viral Testing: Conduct assessments of potential viral contaminants in raw materials.
• Designing Spiking Studies: Utilize appropriate viral models and ensure these studies reflect realistic worst-case scenarios.
• Analysis of Viral Clearance Results: Evaluate the effectiveness of the viral clearance process, using statistical methods to ensure confidence in the results.

Closed and Single-Use Systems in ATMP Manufacturing

The application of closed systems and single-use systems is integral to the aseptic manufacturing environment, helping to reduce contamination risks associated with the handling of biological materials. The design and implementation of these systems require thorough planning and validation.

1. Design and Validation of Closed Systems

Closed systems minimize exposure to external contaminants during the manufacturing process. Validating these systems involves:

• System Design Review: Assess all components involved in the closed systems for suitability and sterility assurance.
• Performance Validation: Conduct validation studies to confirm that the closed systems maintain sterility and function as intended throughout the use.

2. Implementation of Single-Use Systems

Single-use systems are increasingly favored in the sector for their efficiency and lower risk of cross-contamination. Key validation steps include:

• Component Verification: Check all single-use components against specifications for integrity and performance.
• End-to-End Process Validation: A comprehensive review of handling, usage, and disposal of single-use systems during the production cycle.

Aseptic Controls as per Annex 1 Expectations

Manufacturers must adhere to stringent aseptic controls, especially in producing ATMPs. The revision of Annex 1 to Eudralex Volume 4 emphasizes the importance of maintaining sterility assurance throughout production.

1. Understanding Annex 1 Requirements

The current framework under Annex 1 emphasizes the following:

• Environmental Controls: Ensure a controlled environment with appropriate classifications for clean areas.
• Staff Training and Practices: Provide personnel with rigorous training on aseptic practices.
• Equipment Maintenance: Set a regime for routine and emergency equipment maintenance ensuring functionality and sterility.

2. Implementing Aseptic Techniques in Production

The execution strategy should involve thorough evaluations of aseptic techniques including:

• Gowning Procedures: Employ systematic gowning practices to ensure the sterility of personnel.
• Material Transfer Techniques: Utilize validated methods for the transfer of materials into the cleanroom.

Establishing a Chain of Identity Custody (COI) and Chain of Custody (COC)

Establishing a robust Chain of Identity (COI) and Chain of Custody (COC) is paramount in managing patient material and clinical samples. This ensures traceability and accountability throughout the manufacturing process. Key practices include:

• Documentation Practices: Implement rigorous documentation efforts to trace all materials utilized in the manufacturing process.
• Auditing Mechanisms: Conduct regular audits to confirm compliance with established COI and COC requirements.
• Use of Technology: Leverage technology such as barcoding and RFID systems to enhance traceability and minimize human errors.

Continuous Process Verification as an Enhanced Control Mechanism

In addition to PPQ, Continuous Process Verification (CPV) provides an ongoing assurance of process performance and product quality. In the context of ATMPs, CPV involves:

1. Implementing Real-Time Monitoring Systems

Utilize real-time monitoring of critical parameters to identify variations promptly:

• Data Acquisition Systems: Employ systems that automatically gather real-time data from the manufacturing process.
• Statistical Process Control (SPC): Apply SPC techniques to monitor variations and establish control limits.

2. Data Analysis and Feedback Loops

Establish a structured feedback mechanism that includes:

• Regular Review of Data: Implement a cycle of reviewing process data to identify trends and anomalies.
• Corrective Actions: Develop protocols for rapid escalation and corrective actions when deviations are observed.

Conclusion

The development of an effective PPQ strategy for ATMPs entails numerous layers of rigorous assessment, validation, and ongoing monitoring. By incorporating principles of viral clearance validation, understanding the importance of spiking studies, and leveraging closed and single-use systems within aseptic controls under Annex 1 expectations, professionals can ensure a robust manufacturing strategy that meets regulatory expectations and, most importantly, guarantees patient safety and product efficacy.

In summary, adhering to a structured framework for both PPQ and CPV not only fulfils regulatory obligations as set by the FDA, EMA, and other governing bodies but ultimately embodies the commitment to quality and reliability intrinsic to biotechnology and pharmaceutical industries.